英夫利昔单抗治疗克罗恩氏病的临床效果

目的观察英夫利昔单抗治疗克罗恩氏病的临床疗效。方法将60例克罗恩氏病患者随机分为对照组和治疗组,各30例。对照组予综合治疗,治疗组在综合治疗基础上给予静脉输注英夫利昔单抗5 mg/kg,分别于患者用药0、2、6周及以后每隔8周予相同剂量维持,共8次,观察2组治疗前后临床症状缓解,生化指标恢复及内镜下病理改善情况。结果与对照组相比,治疗组腹胀、腹痛等临床症状明显缓解(对照组治疗有效率为10.0%,治疗组为73.3%),生化指标ESR、CRP明显下降,内镜下病理明显改善(对照组内镜下缓解率为10.0%,内镜下改善率为6.7%,治疗组内镜下缓解率为66.7%,内镜下改善率为33.3%),差异均有统计学意义(P<0.05)。结论使用英夫利昔单抗可明显提高克罗恩氏病患者的临床治疗效果,改善生活质量,值得临床推广应用。

Objective To observe the clinical effect of therapy of infliximab on patients of crohn＇s disease. Methods A total of 60 cases of crohn＇s disease were randomly divided into control group and treatment group with 30 cases per group. The control group received combined therapy, while the treatment group was treated with intravenous infliximab 5 mg/kg besides the combined therapy, respectively in patients with medication for 0, 2, 6 weeks and every 8 weeks later in the same dose, a total of 8 times. Clinical symptoms, the restore of biochemical index and the improvement of endoscopic pathology were assessed before and after treatment. Results Compared with control group, abdominal distension, abdominal pain and other clinical symptoms（the treatment of efficient was 10.0% in the control group, it was 73.3% in the treatment group）, biochemical index of the ESR and CRP decreased obviously, endoscopic pathological （the endoscopic remission rate was 10.0%, the endoscopic improvement rate was 6.7% in the control group; they were 66.7% and 33.3% in the treatment group）improved significantly in the treatment group, the difference was statistically significant （P 〈 0.05）. Conclusion Infliximab can significantly improve the clinical treatment effect of crohn＇s disease, improve the quality of life, It is worthy of clinical popularization and application.